As recently as 2011, treatment options for late stage melanoma (stage IV) were very limited and only offered small improvements, however, upon the approval of vemurafenib, a B-RAF inhibitor, initial results were promising in patients positive for the mutated B-RAF protein, roughly 40–60% of people diagnosed with melanoma [4]. This evidence concerns the gene BRAF and melanoma.